The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Analysts believe each of the stocks below has the potential to at least double in price, although the three firms also carry ...

After dropping by 15.74% to close at $1,707.94 yesterday, the stock could continue to pull back today. Shares fell after ...

This was the stock's second consecutive day of losses.

Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating ...

The approval marks a significant milestone for Novavax Inc. (NASDAQ:NVAX), aligning with the changing regulatory landscape ...

Shares of vaccine makers saw an uptick in the latest trading session, with Moderna Inc (BMV:MRNA). (NASDAQ:MRNA) leading the ...

GAITHERSBURG, MD, USA I May 19, 2025 I Novavax, Inc. (Nasdaq: NVAX) today announced that the U.S. Food and Drug Administration (FDA) has approved the ...

At 2:05 p.m., the Dow Jones Industrial Average rose 101.99 points, or 0.23%, to 42,756.73, the S&P 500 lost 1.25 points, or 0.02%, to 5,957.07 and the Nasdaq Composite lost 21.44 points, or 0.11%, to ...

Tesla's Chinese rival Xiaomi announced its electric SUV set to compete with Tesla's Model Y will be launched Thursday. TXNM ...